A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

NCT06319456 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

CLL/SLL

Interventions

DRUG: Lisaftoclax (APG-2575)
DRUG: Acalabrutinib
DRUG: Fludarabine
DRUG: Cyclophosphamide，CTX
DRUG: Rituximab
DRUG: Chlorambucil

Sponsor

Ascentage Pharma Group Inc.